Hill-Rom Holdings, Inc. (HRC) SVP Sells $82,990.00 in Stock

Hill-Rom Holdings, Inc. (NYSE:HRC) SVP Paul Sherwood Johnson sold 1,000 shares of the stock in a transaction that occurred on Wednesday, December 13th. The stock was sold at an average price of $82.99, for a total value of $82,990.00. Following the transaction, the senior vice president now directly owns 1,066 shares in the company, valued at approximately $88,467.34. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Shares of Hill-Rom Holdings, Inc. (NYSE:HRC) opened at $83.25 on Monday. The company has a current ratio of 1.77, a quick ratio of 1.34 and a debt-to-equity ratio of 1.55. The firm has a market capitalization of $5,479.60, a P/E ratio of 21.57, a PEG ratio of 1.77 and a beta of 1.19. Hill-Rom Holdings, Inc. has a 1 year low of $54.80 and a 1 year high of $85.25.

Hill-Rom (NYSE:HRC) last announced its quarterly earnings results on Friday, November 3rd. The medical technology company reported $1.32 earnings per share for the quarter, topping analysts’ consensus estimates of $1.27 by $0.05. The business had revenue of $738.30 million for the quarter, compared to analysts’ expectations of $731.10 million. Hill-Rom had a return on equity of 20.27% and a net margin of 4.87%. The business’s quarterly revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.18 EPS. research analysts predict that Hill-Rom Holdings, Inc. will post 4.26 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 29th. Investors of record on Friday, December 15th will be given a $0.18 dividend. This represents a $0.72 annualized dividend and a yield of 0.86%. The ex-dividend date of this dividend is Thursday, December 14th. Hill-Rom’s dividend payout ratio is currently 36.18%.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas increased its position in Hill-Rom by 0.3% in the 2nd quarter. Teacher Retirement System of Texas now owns 5,194 shares of the medical technology company’s stock valued at $413,000 after acquiring an additional 14 shares during the period. Stifel Financial Corp increased its position in Hill-Rom by 0.5% in the 2nd quarter. Stifel Financial Corp now owns 4,379 shares of the medical technology company’s stock valued at $349,000 after acquiring an additional 23 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in Hill-Rom by 0.5% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,734 shares of the medical technology company’s stock valued at $695,000 after acquiring an additional 46 shares during the period. Utah Retirement Systems increased its position in Hill-Rom by 0.8% in the 2nd quarter. Utah Retirement Systems now owns 12,013 shares of the medical technology company’s stock valued at $956,000 after acquiring an additional 100 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Hill-Rom by 10.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,201 shares of the medical technology company’s stock valued at $175,000 after acquiring an additional 204 shares during the period. Hedge funds and other institutional investors own 82.35% of the company’s stock.

HRC has been the topic of a number of research analyst reports. Needham & Company LLC reduced their target price on Hill-Rom from $93.00 to $90.00 and set a “buy” rating on the stock in a report on Monday, November 6th. Zacks Investment Research upgraded Hill-Rom from a “hold” rating to a “buy” rating and set a $90.00 price target on the stock in a research report on Friday, October 27th. KeyCorp reiterated a “buy” rating and set a $89.00 price target (up from $82.00) on shares of Hill-Rom in a research report on Sunday, November 5th. Barclays increased their price target on Hill-Rom from $86.00 to $90.00 and gave the stock an “overweight” rating in a research report on Monday, November 6th. Finally, ValuEngine cut Hill-Rom from a “buy” rating to a “hold” rating in a research report on Saturday, November 4th. Five investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $89.57.

COPYRIGHT VIOLATION WARNING: This article was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://sportsperspectives.com/2017/12/18/hill-rom-holdings-inc-hrc-svp-sells-82990-00-in-stock.html.

Hill-Rom Company Profile

Hill-Rom Holdings, Inc is a global medical technology company. The Company operates through four segments: North America Patient Support Systems, International Patient Support Systems, Front Line Care and Surgical Solutions. The Company’s products and services include Patient Support Systems, Front Line Care and Surgical Solutions.

Insider Buying and Selling by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply